Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

  title={Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.},
  author={W. Boden and J. Probstfield and T. Anderson and B. Chaitman and Patrice Desvignes-Nickens and K. Koprowicz and R. Mcbride and K. Teo and W. Weintraub},
  journal={The New England journal of medicine},
  volume={365 24},
  • W. Boden, J. Probstfield, +6 authors W. Weintraub
  • Published 2011
  • Medicine
  • The New England journal of medicine
  • BACKGROUND In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin therapy. It is unclear whether extended-release niacin added to simvastatin to raise low levels of high-density lipoprotein (HDL) cholesterol is superior to simvastatin alone in reducing such residual risk. METHODS We randomly assigned eligible patients to receive extended-release niacin, 1500 to… CONTINUE READING
    2,229 Citations

    Figures, Tables, and Topics from this paper

    Paper Mentions

    Interventional Clinical Trial
    The primary objective of this study is to generate preliminary data on the effects of a short-term diet of either fast food or Mediterranean type diet on HDL and microbiota… Expand
    ConditionsDiet Modification, HDL, Inflammation
    Observational Clinical Trial
    Aortic valve stenosis (AVS), the most common form of valve disease in the western world, afflicts more than 1 million individuals in North America [1] and the burden of AVS is high… Expand
    ConditionsHeterozygous Familial Hypercholesterolemia
    Interventional Clinical Trial
    Treatment using statin has been decreased the risk of cardiovascular events in pre-dialysis CKD population. Supplementation with omega-3 fatty acid (FA) lowers the risk of… Expand
    ConditionsChronic Kidney Disease
    Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
    • 852
    • PDF
    Effects of dalcetrapib in patients with a recent acute coronary syndrome.
    • 1,536
    • PDF
    Effects of extended-release niacin with laropiprant in high-risk patients.
    • 1,014
    • PDF
    Combination therapy in dyslipidemia: where are we now?
    • 46
    • Highly Influenced
    Niacin in cardiovascular patients receiving statins.
    • 4
    Lipid-lowering therapy in older persons
    • W. Aronow
    • Medicine
    • Archives of medical science : AMS
    • 2015
    • 22
    • PDF
    Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
    • 465
    • PDF
    Treatment of Hypercholesterolemia
    • 3
    • PDF


    Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
    • 1,435